Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy

Experimental Hematology & Oncology

Ji Xu¹  Yujie Wu¹  Shuai Wang¹  Run Zhang¹  Lijuan Chen¹  Liying Zhu¹  Han Zhu¹  Jianyong Li¹  Lina Zhang¹ 

[1] Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, 210029, Nanjing, China;

关键词: Tumor necrosis factor -α;    Etanercept;    Cytokine release syndrome;    Chimeric antigen receptor T cell therapy;    Multiple myeloma;   

DOI  :  10.1186/s40164-021-00209-2

来源: Springer

【 摘 要 】

Cytokine release syndrome (CRS) is the most common toxicity induced by chimeric antigen receptor (CAR) T cell therapy. At present, anti-IL-6 agents including tocilizumab and siltuximab have been applied in the treatment of CRS. However, tocilizumab and siltuximab are expensive and some patients fail to respond to anti-IL-6 therapy, which urges the need for new drugs. In clinical practice, we found some patients with multiple myeloma developed markedly increased levels of tumor necrosis factor (TNF)- α during the CRS period after anti-BCMA CAR T cell infusion. Here we present the successful use of TNF-α inhibitor (etanercept) to cure CRS in three patients. The introduction of etanercept did not alter patients' response to CAR T cell therapy and no adverse event was observed directly related to the administration of etanercept. Furthermore, in vitro experiments confirmed that etanercept did not affect the proliferation and effector function of CAR T cells. Our results indicate that etanercept could be considered as a treatment option for CRS in patients with significantly elevated TNF-α levels.

【 授权许可】

CC BY